-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Assumes RAPT Therapeutics at Buy, Announces Price Target of $6

Benzinga·05/22/2025 11:27:42
Listen to the news
HC Wainwright & Co. analyst Emily Bodnar assumes RAPT Therapeutics (NASDAQ:RAPT) with a Buy rating and announces Price Target of $6.